Latest Pure Bioscience (PURE) Headlines PURE Bi
Post# of 24
Posted On: 03/13/2014 1:34:35 AM
Latest Pure Bioscience (PURE) Headlines
PURE Bioscience Hosts Q2 Results Conference Call March 13th, 2014 and Reviews Progress of SDC-Based Food Safety Solutions Strategy
Marketwire - Mon Mar 03, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Thursday, March 13th, 2014 at 1:30pm PDT (4:30pm EDT).
PURE Bioscience Business Update and Goals -- Food Safety Strategy Gaining Traction
Marketwire - Thu Jan 30, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced that execution of its Food Safety Solutions Strategy continues to progress. The Company also announced its goals for calendar year 2014.
PURE Developing SDC-Based Antimicrobial for Direct Food Application
Marketwire - Tue Jan 28, 7:31AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced progress in development of a SDC-based antimicrobial for direct food contact. The Company is testing formulations to be used as a rinse or processing aid on produce, poultry, and meats.
PURE Completes Phase One Technology Transfer for Expanded Production -- Intercon SDC Facility Online
Marketwire - Thu Jan 23, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has completed the first phase of the SDC technology transfer to its collaboration partner, Intercon Chemical Company (ICC). The first phase consists of the partial transfer of PURE's unique and proprietary SDC manufacturing process into a new and dedicated production facility at ICC's St. Louis manufacturing location.
PURE's SDC-Based Food Safety Solutions Strategy Gains Traction -- Initial Orders From Three Food Processors
Marketwire - Thu Jan 16, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced continued progress on its strategic positioning as a food safety solution which was launched this past Fall.
5W Public Relations Expands Corporate Practice, Adds PURE Bioscience, Inc. to Client Roster
PR Newswire - Wed Dec 18, 7:45AM CST
5W Public Relations, one of the 25 largest independent public relations firms in the U.S., announced the addition of PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial agent, to its diverse roster of corporate clients.
PURE Bioscience Reports Fiscal First Quarter 2014 Financial Results
Marketwire - Thu Dec 12, 3:05PM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2013 (Fiscal Q1 2014).
PURE Announces Strategic Collaboration With Intercon Chemical Company
Marketwire - Thu Dec 12, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has entered into a five-year strategic collaboration agreement with St. Louis-based Intercon Chemical Company (ICC). The agreement consists of a multi-pronged approach to accelerate the commercialization of PURE's unique and proprietary SDC-based products.
PURE Bioscience Hosts Q1 Results Conference Call December 12, 2013
Marketwire - Mon Dec 09, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Thursday, December 12, 2013 at 2:00 PM Pacific Time (5:00 pm Eastern Time).
PURE Announces Distribution Agreement With Brenntag Specialties, Inc.
Marketwire - Mon Dec 02, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has entered into a three-year distribution agreement with Brenntag Specialities, Inc. ("Brenntag"). The non-exclusive agreement provides Brenntag the worldwide rights to distribute PURE's unique and proprietary SDC-based antimicrobial SILVERION(R) 2400 as an active ingredient or preservative for use in personal care products.
PURE Bioscience to Present at 6th Annual LD MICRO Conference
Marketwire - Mon Nov 25, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Peter C. Wulff, CFO & COO, will present at the Sixth Annual LD MICRO Conference on Thursday, December 5th, at 1:00 PST, at the Luxe Hotel Sunset Boulevard in Los Angeles.
PURE Bioscience Reports Fiscal 2013 Year End Financial Results
Marketwire - Thu Oct 24, 3:05PM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2013 ("Fiscal 2013").
PURE Bioscience to Host Year End Results Conference Call October 24, 2013
Marketwire - Tue Oct 22, 7:30AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Thursday, October 24, 2013 at 2:00 PM Pacific Time (5:00 pm Eastern Time). In addition to reviewing fiscal year end 2013 financial results, the purpose of this call is to:
PURE Bioscience names William Otis as sixth board member
M2 - Wed Oct 09, 5:12AM CDT
Antimicrobial company PURE Bioscience (OTCQB
URE) revealed on Tuesday the appointment of William Otis to its board of directors.
PURE Bioscience Appoints Sixth New Board Member
Marketwire - Tue Oct 08, 7:30AM CDT
PURE Bioscience (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the appointment of William Otis to its Board of Directors. Mr. Otis is the sixth member to join the Company's Board of Directors.
PURE Bioscience Appoints New CEO
Marketwire - Tue Sep 10, 7:30AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the appointment of Hank Lambert as its new Chief Executive Officer. Mr. Lambert replaces the interim CEO, Dave Pfanzelter, who remains as Chairman of the Board. The company reported that the management change is part of its previously announced reorganization establishing new and experienced leadership focused on commercialization of SDC technology in the food industry as a unique and proprietary antimicrobial agent to protect consumer safety against various pathogens.
PURE Bioscience expands sales and marketing team with addition of Cliff Wechsler & Tom Myers
M2 - Thu Aug 29, 4:35AM CDT
Antimicrobial company PURE Bioscience (OTCQB URE) said on Wednesday that it is strengthening of its sales and marketing leadership team to drive the commercialisation of SDC technology to protect consumer safety against various pathogens in the food industry.
PURE Bioscience Strengthens Sales and Marketing Organization
Marketwire - Wed Aug 28, 7:30AM CDT
PURE Bioscience (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the strengthening of its sales and marketing leadership team. The company appointed Cliff Wechsler as its new Executive Vice President of Sales, and Tom Myers assumed the position of Executive Vice President of Marketing and Product Development. The company reported that the management change established the leadership to drive the commercialization of SDC technology in the food industry as a novel and proprietary antimicrobial agent to protect consumer safety against various pathogens.
Delisting of Securities of SmartHeat Inc., Ampal-American Israel Corporation, PURE Bioscience, Inc., Urologix, Inc. and Strategic Diagnostics Inc. From The NASDAQ Stock Market
GlobeNewswire - Mon Aug 19, 3:05PM CDT
The NASDAQ Stock Market announced today that it will delist the common stock of SmartHeat Inc. SmartHeat Inc.'s stock was suspended on November 09, 2012 and has not traded on NASDAQ since that time.
OTC Daily Alert Stock Watch - PURE Bioscience, Inc. (OTCQB: PURE)
WorldStockWire - Sat Aug 17, 5:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
PURE Bioscience Hosts Q2 Results Conference Call March 13th, 2014 and Reviews Progress of SDC-Based Food Safety Solutions Strategy
Marketwire - Mon Mar 03, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Thursday, March 13th, 2014 at 1:30pm PDT (4:30pm EDT).
PURE Bioscience Business Update and Goals -- Food Safety Strategy Gaining Traction
Marketwire - Thu Jan 30, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced that execution of its Food Safety Solutions Strategy continues to progress. The Company also announced its goals for calendar year 2014.
PURE Developing SDC-Based Antimicrobial for Direct Food Application
Marketwire - Tue Jan 28, 7:31AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced progress in development of a SDC-based antimicrobial for direct food contact. The Company is testing formulations to be used as a rinse or processing aid on produce, poultry, and meats.
PURE Completes Phase One Technology Transfer for Expanded Production -- Intercon SDC Facility Online
Marketwire - Thu Jan 23, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has completed the first phase of the SDC technology transfer to its collaboration partner, Intercon Chemical Company (ICC). The first phase consists of the partial transfer of PURE's unique and proprietary SDC manufacturing process into a new and dedicated production facility at ICC's St. Louis manufacturing location.
PURE's SDC-Based Food Safety Solutions Strategy Gains Traction -- Initial Orders From Three Food Processors
Marketwire - Thu Jan 16, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced continued progress on its strategic positioning as a food safety solution which was launched this past Fall.
5W Public Relations Expands Corporate Practice, Adds PURE Bioscience, Inc. to Client Roster
PR Newswire - Wed Dec 18, 7:45AM CST
5W Public Relations, one of the 25 largest independent public relations firms in the U.S., announced the addition of PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial agent, to its diverse roster of corporate clients.
PURE Bioscience Reports Fiscal First Quarter 2014 Financial Results
Marketwire - Thu Dec 12, 3:05PM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2013 (Fiscal Q1 2014).
PURE Announces Strategic Collaboration With Intercon Chemical Company
Marketwire - Thu Dec 12, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has entered into a five-year strategic collaboration agreement with St. Louis-based Intercon Chemical Company (ICC). The agreement consists of a multi-pronged approach to accelerate the commercialization of PURE's unique and proprietary SDC-based products.
PURE Bioscience Hosts Q1 Results Conference Call December 12, 2013
Marketwire - Mon Dec 09, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Thursday, December 12, 2013 at 2:00 PM Pacific Time (5:00 pm Eastern Time).
PURE Announces Distribution Agreement With Brenntag Specialties, Inc.
Marketwire - Mon Dec 02, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has entered into a three-year distribution agreement with Brenntag Specialities, Inc. ("Brenntag"). The non-exclusive agreement provides Brenntag the worldwide rights to distribute PURE's unique and proprietary SDC-based antimicrobial SILVERION(R) 2400 as an active ingredient or preservative for use in personal care products.
PURE Bioscience to Present at 6th Annual LD MICRO Conference
Marketwire - Mon Nov 25, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Peter C. Wulff, CFO & COO, will present at the Sixth Annual LD MICRO Conference on Thursday, December 5th, at 1:00 PST, at the Luxe Hotel Sunset Boulevard in Los Angeles.
PURE Bioscience Reports Fiscal 2013 Year End Financial Results
Marketwire - Thu Oct 24, 3:05PM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2013 ("Fiscal 2013").
PURE Bioscience to Host Year End Results Conference Call October 24, 2013
Marketwire - Tue Oct 22, 7:30AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Thursday, October 24, 2013 at 2:00 PM Pacific Time (5:00 pm Eastern Time). In addition to reviewing fiscal year end 2013 financial results, the purpose of this call is to:
PURE Bioscience names William Otis as sixth board member
M2 - Wed Oct 09, 5:12AM CDT
Antimicrobial company PURE Bioscience (OTCQB
URE) revealed on Tuesday the appointment of William Otis to its board of directors. PURE Bioscience Appoints Sixth New Board Member
Marketwire - Tue Oct 08, 7:30AM CDT
PURE Bioscience (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the appointment of William Otis to its Board of Directors. Mr. Otis is the sixth member to join the Company's Board of Directors.
PURE Bioscience Appoints New CEO
Marketwire - Tue Sep 10, 7:30AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the appointment of Hank Lambert as its new Chief Executive Officer. Mr. Lambert replaces the interim CEO, Dave Pfanzelter, who remains as Chairman of the Board. The company reported that the management change is part of its previously announced reorganization establishing new and experienced leadership focused on commercialization of SDC technology in the food industry as a unique and proprietary antimicrobial agent to protect consumer safety against various pathogens.
PURE Bioscience expands sales and marketing team with addition of Cliff Wechsler & Tom Myers
M2 - Thu Aug 29, 4:35AM CDT
Antimicrobial company PURE Bioscience (OTCQB
URE) said on Wednesday that it is strengthening of its sales and marketing leadership team to drive the commercialisation of SDC technology to protect consumer safety against various pathogens in the food industry. PURE Bioscience Strengthens Sales and Marketing Organization
Marketwire - Wed Aug 28, 7:30AM CDT
PURE Bioscience (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the strengthening of its sales and marketing leadership team. The company appointed Cliff Wechsler as its new Executive Vice President of Sales, and Tom Myers assumed the position of Executive Vice President of Marketing and Product Development. The company reported that the management change established the leadership to drive the commercialization of SDC technology in the food industry as a novel and proprietary antimicrobial agent to protect consumer safety against various pathogens.
Delisting of Securities of SmartHeat Inc., Ampal-American Israel Corporation, PURE Bioscience, Inc., Urologix, Inc. and Strategic Diagnostics Inc. From The NASDAQ Stock Market
GlobeNewswire - Mon Aug 19, 3:05PM CDT
The NASDAQ Stock Market announced today that it will delist the common stock of SmartHeat Inc. SmartHeat Inc.'s stock was suspended on November 09, 2012 and has not traded on NASDAQ since that time.
OTC Daily Alert Stock Watch - PURE Bioscience, Inc. (OTCQB: PURE)
WorldStockWire - Sat Aug 17, 5:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
(0)
(0)PURE Bioscience (PURE) Stock Research Links
Scroll down for more posts ▼